| Biomimedica is a medical device company that is pioneering new approaches to joint repair through synthetic cartilage. |
| Lypro BioSciences is a specialty biopharma company whose technology addresses the adverse effects arising from the insoluble nature of certain hydrophobic drugs – drugs that are poorly soluble in the blood stream. |
| Visioneering provides new breakthrough, on-eye/in-eye optical lens design for treating presbyopia. |
| Amplyx is an early stage drug delivery company founded in 2006. It has developed a unique, patented chemical platform that leverages the enormous pharmacokinetic benefits of large protein molecules (e.g. PEGylation, human albumen binding) in a simple, small drug molecule format. |
| ChinaBio Therapeutics is a near-virtual U.S.-based drug development company with headquarters in California and R&D operations planned in Suzhou, China, near Shanghai. ChinaBio’s business model is to in-license early stage drug candidates from the West, move them to human proof-of-concept in China, then out-license the drugs to major pharma or biotechs or spin them out to VC-backed ventures. |
| Satoris was formed with the mission of developing and commercializing diagnostic technologies for molecular profiling of neurological disorders. The first proprietary test developed by Satoris targets Alzheimer’s disease (AD), currently with 4 -5 million U.S. patients. These tests will be used to assist pharma in AD drug development as well as clinicians in diagnosing AD cases. |
| Textronics, Inc. is a leader in the development of wearable sensors for use in fitness and health monitoring. The Company’s textile sensors capture comprehensive data from the body and are designed to be seamlessly integrated into everyday garments. |
| VaxArt, Inc. is a biotechnology company focused on the development of oral vaccines. |
| Velomedix, Inc. is a medical device company developing a rapid tissue protective hypothermic therapy. |
| Bioabsorbable Therapeutics, Inc., a Menlo Park medical device company, is developing a novel, proprietary bio-degradable coronary stent. Other investors include Synergy Partners, an LSA VC-member firm |
| Breathe Technologies, Inc., based in Fremont, California, is developing proprietary medical devices to treat respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD), a serious disease that affects over 10 millions Americans. Breathe’s technology is a portable oxygen delivery and ventilation system that will enable severe COPD patients to perform normal daily activities (talking, walking and exercising) and improve their natural breathing mechanics. The company has completed proof-of-principle product development and is currently completing animal studies and finalizing clinical protocols for commencement of US and EU trials later this year. Life Science Angels participated in this $4 million Series A round led by Synergy Ventures. |
| Fluxion Biosciences, Inc. is developing a family of high-throughput devices to perform single-cell assays critical to drug discover and development, including the recently FDA-mandated HERG test. Utilizing proprietary microfluidics and cell handling technologies developed at UC Berekely, Fluxion’s devices will be significantly less costly than current equipment, while increasing throughput and improving sensitivity and specificity. The funds will be used to advance product development |
| Nanostim, Inc. |
| NeuroHealing Pharmaceuticals, Inc., is a Newton, Massachusetts-based clinical stage company developing therapies to improve the neuro-rehabilitation process and functional outcome for patients who have suffered debilitating injuries to the central nervous system (CNS). NeuroHealing has two drugs ready for Phase 2 clinical trials. The first is designed to promote consciousness recovery in people who are or have been in a coma, and is currently being tested in an open label trial. The second candidate is being developed for treatment of sialorrhea (drooling or un-controlled salivation), a debilitating social problem associated with Parkinson’s Disease, cerebral palsy, ALS and other neurological disorders. A Phase II double-blind placebo study in Parkinson’s Disease patients is pending. Life Science Angels led this $500,000 round. |
| VasoNova, Inc., is developing a self-guided PICC catheter to improve placement efficient, patient throughput and decrease procedure time and expense. VasoNova’s device utilizes a proprietary sensor technology together with a handheld device to guide insertion. LSA participated in this A round led by RCT Bioventures and Coronis Medical Ventures, both LSA VC-members. |
| Zogenix, Inc. (presented as SJ2) is a specialty pharma focused on the development and commercialization of therapies for CNS disorders and pain. Zogenix was formed by merging SJ2, a spinout of Aradigm, with the San Diego startup, Zogenix, and acquiring the rights to Aradigm’s Intraject® program. Clarus Ventures, an LSA venture member, and Domain associates led the $60MM Series A round in which LSA participated. The funding will be used to advance the clinical and commercial development of Intraject sumatriptan, the first needle-free, single-use, disposable, subcutaneous delivery system targeting the $2.5 billion migraine market. |
| CoMentis, Inc. (funded as Athenagen), a Bay Area pharmaceutical company founded by two Stanford University scientists with entrepreneurial experience, is engaged in the development of small-molecule drugs designed to either inhibit or enhance angiogenesis. CoMentis’s two development platforms are based on a new angiogenesis pathway discovered at Stanford University, and technologies acquired from Osprey and Zapaq. CoMentis now has three clinical-stage drugs. Life Science Angels participated in the $5.7 milling Series A financining with Sanderling, whothen led the $50 millions B round. |
| CODA Genomics, Inc. is an Irvine, California company providing products and services enabling researchers to synthesize and assemble genes, transcription systems and entire genomes using synthetic oligonucleotide assembly. CODA technology, a computationally optimization algorithm coupled with improved laboratory biological methods, improves the process for constructing a synthetic DNA gene that expresses a desired protein. Initial markets include academic research and biotechnolgy and pharmaceutical companies developing protein-based drugs. Life Science Angels led this $1.6 million B round financing. |
| N Spine, Inc., a San Diego medical device company, is focused on posterior dynamic stabilization of the lumbar spine via minimally invasive surgery. The company’s primary product is a titanium pedicle screw system with a novel rod design that provides dynamic support, not rigid fixation, to the spinal segment. Life Science Angels led the $2.2 million Series A financing. |
| Novasys Medical, Inc., a Newark, California medical device company, develops innovative therapies in women’s health. The company’s initial focus is the development and commercialization of the Renessa™ System, a proprietary, non-surgical approach to the treatment of female stress urinary incontinence, which has just received FDA approval. Novasys has received $38 million in venture funding. Life Science Angels acquired shares from a private shareholder at a discount to the latest C round. |
| Pegasus Biologics is an Irvine, California medical device company developing and manufacturing bioimplants for use in soft tissue reinforcement specifically for orthopedics, sports medicine, neurosurgical and spine applications. Their patented UltiFix® and UltiSter™ tecnologies have applications for the stabilization and sterilization of biological tissue, of animal or human origin for use in orthopedic, spine and neurological applications. Life Science Angels participated in this $10.2MM Series B funding with Three Arch Partners and Frazier HealthCare Ventures |
| PixelOptics, a privately-held company in Roanoke , Virginia , addresses the $50 billion gobal vision care ind ustry with its electro-active optics technology platform. This patented technology enables lenses to adjust dynamically, providing optimum vision for the correction of presbyopia, known to impact 93% of the population over 45 years of age, and other visual disorders. This technology can also provide Supervision – the ability to see better than 20/20 or even 20/10 – which is of great interest to the military. Life Science Angels led this bridge funding which will be used to advance product development. |
| Uptake Medical Corporation is a Seattle-based medical device company dedicated to improving the lives of patients suffering from emphysema and chronic obstructive pulmonary disease (COPD). Uptake Medical is currently developing a safe and effective, energy-based, bronchoscopic lung volume reduction (BLVR) treatment aimed at improving lung function and patient quality of life without the attendant risks and costs associated with surgical LVR, endobronchial glues, valves and occluders. Life Science Angels led the angel round. |
| InnerScope is a revolutionary media research firm that uses recent advances in biomeasures and proprietary software analysis to measure an audiences’ emotional engagement to any form of media stimulus. |
| Retrotope is a privately held company focused on the development of ways of controlling metabolic processes associated with the oxidative stress conditions. |
| CV Ingenuity CV Ingenuity Corp. is developing drug-eluting balloon platform technology for cardiac and peripheral arteries. |
| Advanced Cardiac Therapeutics (ACT) This technology provides the physician an assessment of the effectiveness of the treatment of such disorders as Atrial Fibrillation in real time, during the procedure. |
| Catheter Connections is a private, venture-backed company founded in 2008 that develops innovative infection control and vascular access products |
| Theron soon to be announced |
| Altheos is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. |
